Li Wang, Ph.D.

Abbvie

Li Wang, PhD, is currently Senior Director and Head of Statistical Innovation group in AbbVie.  Li is leading Design Advisory which provides strategic and quantitative consulting as requested to all Development teams in all Therapeutic Areas to facilitate innovative thinking and complex innovative design evaluation. Li also co-leads Development Advanced Analytics capability in AbbVie to drive Machine Learning and Advanced Analytics research and application in Development.  Prior to this senior leadership role, he led Immunology and Solid Tumor statistical design and strategy discussions and multiple ML, RWE and Bayesian innovation projects from 2017 to 2019. From 2006 to 2017, he contributed to and subsequently led several NDAs and SNDAs including blockbusters Eliquis, Onglyza and Rinvoq. He is enthusiastic in teaching statistical courses to non-statisticians, and investigating/ promoting novel statistical and machine learning methodologies. 

He is very active in statistical communities as board member of ICSA (2023-2025), Chair-elect of Development Committee of SCT (2024), Chair of Education Committee of DIA, Cytel Innovation Advisory Board, DIA biostatistics industry and regulator forum planning committee and past chair of ICSA Midwest Chapter.

Li received his B.S. in Applied Mathematics from Peking University and his Ph.D in Statistics from Virginia Tech.